Drug fails in autism study.
On Jan. 5, Repligen of Waltham, Mass., the biotech company seeking to develop secretin for use against autism, announced the disappointing results of its latest trial, which involved 132 children.
A protein that occurs naturally in the gut, secretin gained notice as a potential autism cure in 1998, when news media reported a ease in which the substance seemingly cured an autistic boy. Neuroscientists were pleasantly surprised when they later discovered in rodent studies that nerve cells in brain regions implicated in autism respond to secretin, a finding that offered a biological rationale for a gut protein influencing autism (SN: 11/17/01, p. 314).
Although Repligen didn't rule out further tests of secretin for some people with autism, the company said it also plans to investigate the protein as a treatment for schizophrenia.--J.T.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Brief Article|
|Date:||Jan 31, 2004|
|Previous Article:||Danger on deck? Kids may need protection from wood structures in the play yard.|
|Next Article:||Lion skeleton found in Egyptian tomb.|